

Valbiotis to launch Valbiotis®PRO Metabolic Health (Totum•63) for the prevention of metabolic diseases on the French market in February-March 2025

La Rochelle, November 6, 2024 (5:40 PM CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a French scientific research laboratory specializing in the development and marketing of dietary supplements to prevent and combat the metabolic disorders that cause cardiovascular disease, clarifies the timeframe for and shares details about the launch of Valbiotis®PRO Metabolic Health in France, which will take place in February-March, in line with the previously announced schedule (launch in H1 2025).

Based on the patented active substance TOTUM•63, Valbiotis®PRO Metabolic Health is an innovative dietary supplement that provides a natural, non-drug, scientifically tested, plant-based response to moderate dysglycemia, weight management and balancing altered metabolic syndrome parameters.

It addresses a key public health issue: the increase in metabolic diseases, in particular type 2 diabetes. In France, there are 4 million people living with diabetes, and 2 to 3 million more are prediabetic¹. The majority of these cases involve type 2 diabetes, often linked to age, obesity and lifestyle, and for which prevention plays a predominant role.

A clinically tested substance validated by the scientific community

Backed by over 10 years of research and development, Valbiotis®PRO Metabolic Health offers a clinically tested, multi-targeted, preventive solution for moderate dysglycemia and balancing altered metabolic syndrome parameters. This dietary supplement is based on TOTUM•63, a 100% plant-based active ingredient patented in 58 countries, clinically tested on 720 people (4 studies), and validated by the scientific community with 17 presentations at international congresses and 7 publications in international scientific journals.

At the end of 2023, TOTUM•63's full clinical pathway was completed by the Phase II/III REVERSE-IT study, which confirmed its efficacy in reducing fasting blood glucose levels, the main risk factor for type 2 diabetes.

An industrial and commercial strategy aligned with that of Valbiotis®PRO Cholesterol

The launch of Valbiotis®PRO Metabolic Health will benefit from the positive experience of Valbiotis®PRO Cholesterol, on the market in France since May 2024. Its production will also be handled by a French pharmaceutical manufacturer, whose industrial processes have already been validated. Upstream, strategic stocks of plant raw materials have been built up to secure the launch of Valbiotis®PRO Metabolic Health.

¹ Marx, N., et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. European Heart Journal 44, 4043–4140 (2023).

This launch will also be covered by the strategy deployed around Valbiotis^{®PRO} Cholesterol, in terms of sales and marketing. The in-house sales force of 16 Medical Promotion Officers (MPOs) will promote both products jointly during 50/50 visits to the two target prescriber groups in high-potential areas:

- General practitioners, who will be able to recommend Valbiotis^{®PRO} Metabolic Health (sold behind the pharmacy counter)
- Pharmacists, who will be trained in recommending the product and advising patients (over the counter)

In pharmacies, supplied directly by Valbiotis or by wholesalers/distributors, Valbiotis^{®PRO} Metabolic Health will be available in pillboxes at the recommended retail prices of €22.95 for 90 gel capsules and €39.95 for 180 gel capsules. The dietary supplement will also be available in doypacks on the e-commerce site <https://www.valbiotis-healthcare.com/>.

Confirmation of the commercial roadmap

This second commercial launch in France will be followed by that of TOTUM•854 (blood pressure) in 2025, itself followed by the launch of Valbiotis' fourth dietary supplement, TOTUM•448 (hepatic steatosis).

About Valbiotis

Valbiotis is a French scientific research laboratory specializing in the development and marketing of dietary supplements to prevent and combat the metabolic disorders that cause cardiovascular disease.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of natural dietary supplements designed to reduce the risk of the metabolic diseases and cardiovascular risk factors, relying on a multi-target strategy enabled by the use of plants.

In France, Valbiotis is responsible for marketing its own products. Internationally, its products are the subject of licensing agreements.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

+33 5 46 28 62 58

media@valbiotis.com

Financial Communication / Seitosei-Actifin

Marianne Py

+33 1 80 48 25 31

marianne.py@seitosei-actifin.com

Press Relations / Seitosei-Actifin

Jennifer Jullia

+33 1 56 88 11 19

jennifer.jullia@seitosei-actifin.com



Name: Valbiotis
ISIN Code: FR0013254851
Ticker Symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.